Proceedings (Baylor University. Medical Center) · 2026
Yttrium-90 for the treatment of breast cancer liver metastases: a global propensity-matched study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miles Brittany, Mallepally Adarsh, Oza Quaid, Moss Jason
Аннотация
BACKGROUND: Breast cancer is the most common malignancy in women. Despite advancements in monoclonal antibodies and targeted therapies, the prognosis significantly worsens once distant metastases develop. Y-90's benefit for breast cancer liver metastasis (BCLM) patients is largely understudied, as prior retrospective studies have been limited in their cohort size. We evaluated the impact of Y-90 radioembolization on overall survival in BCLM patients in a diverse multi-institutional cohort.
METHODS: A retrospective cohort study was conducted using the TriNetX Research Network comparing Y-90 and non-Y-90 BCLM cohorts. The primary endpoint was overall survival, measured at 3, 6, 9, and 12 months. A total of 25,730 patients were screened for potential inclusion in the study. After propensity-score matching for age, race, and ethnicity, 221 patients were included in each cohort.
RESULTS: At 3, 6, and 9 months, the Y-90 cohort demonstrated a significantly lower mortality risk compared to the non-Y-90 cohort. At 12 months, the mortality risk was statistically similar between the two arms.
CONCLUSION: Y-90 treatment is associated with significantly improved survival out to at least 9 months, providing further evidence for its utility in antitumor efficacy. For patients who have liver-predominant disease or liver-only progression, treatment with Y-90 should be considered a reasonable treatment option.
METHODS: A retrospective cohort study was conducted using the TriNetX Research Network comparing Y-90 and non-Y-90 BCLM cohorts. The primary endpoint was overall survival, measured at 3, 6, 9, and 12 months. A total of 25,730 patients were screened for potential inclusion in the study. After propensity-score matching for age, race, and ethnicity, 221 patients were included in each cohort.
RESULTS: At 3, 6, and 9 months, the Y-90 cohort demonstrated a significantly lower mortality risk compared to the non-Y-90 cohort. At 12 months, the mortality risk was statistically similar between the two arms.
CONCLUSION: Y-90 treatment is associated with significantly improved survival out to at least 9 months, providing further evidence for its utility in antitumor efficacy. For patients who have liver-predominant disease or liver-only progression, treatment with Y-90 should be considered a reasonable treatment option.